Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,510 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president owned 23,554 shares in the company, valued at approximately $8,547,039.98. This trade represents a 6.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $370.33, for a total value of $848,055.70.
• On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04.

Alnylam Pharmaceuticals Stock Up 0.0%

ALNY opened at $359.27 on Friday. The firm has a market cap of $47.46 billion, a P/E ratio of 1,496.96 and a beta of 0.32. The business’s fifty day simple moving average is $418.74 and its 200 day simple moving average is $421.35. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Groupama Asset Managment increased its position in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $662,837,000. Arrowstreet Capital Limited Partnership increased its position in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after acquiring an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $369,943,000. Finally, Holocene Advisors LP acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $194,616,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ALNY shares. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research report on Monday, October 6th. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Bank of America decreased their price target on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. HC Wainwright set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Jefferies Financial Group cut their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $490.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.